could gene medication be harnessed to battle the AIDS?

This time his body controls it with itself, & investigators are trying to good the gene editing that made this possible. "Gene medication techniques have features greatly," said Dr. Otto Yang of the UCLA AIDS virus Institute, 1 place working on this. They Utilize a gene editing tool called zinc finger nucleases, that cut DNA at a precise spot to disable the HIV virus entryway gene. The silver liningThough the initial gene editing experiments were disappointing, there was a silver lining. His research going to have a try the same gene editing — disabling the gene that makes the HIV virus entryway — When saving patients on powerful antiviral medicines for at least a year before discontinuing them.

Oxford BioMedica wins 2nd $hundred mln gene medication contract

Shutterstock photoLONDON, Feb 15 (Reuters) - UK'sOxford BioMedica has won a 2nd $hundred mn contract to supply gene medication material, this time from Bioverativ, that agreed final 30 days to be acquired by Sanofi for $eleven.six bn. Oxford Bio said on Thursday it would receive $five mn upfront & would be eligible for several milestone payments, potentially worth in excess of $hundred mn, plus royalties on discounts of haemophilia therapies that Bioverativ is emerging. The bargain follows a similar $hundred mn contract final year to supply lentiviral vectors, that are used to deliver DNA into cells, for Novartis's pioneering leukaemia curing Kymriah. This time, But, gene & cell medication is coming of age, by the premier products confirmed final year in the U.S. & further on How. Peel Hunt analyst Amy Walker, who averages the stock a purchase, said the Fresh bargain cemented her view that Oxford Bio's technology was "at the forefront of the gene & cell medication revolution".

Oxford BioMedica wins 2nd $hundred mn gene medication contract

referring to LONDON (Reuters) - UK's Oxford BioMedica has won a 2nd $hundred mn contract to supply gene medication material, this time from Bioverativ, that agreed final 30 days to be acquired by Sanofi for $eleven.six bn. Oxford Bio said on Thursday it would receive $five mn upfront & would be eligible for several milestone payments, potentially worth in excess of $hundred mn, plus royalties on discounts of hemophilia therapies that Bioverativ is emerging. The bargain follows a similar $hundred mn contract final year to supply lentiviral vectors, that are used to deliver DNA into cells, for Novartis's pioneering blood cancer curing Kymriah. This time, But, gene & cell medication is coming of age, by the premier products confirmed final year in the U.S. & further on How. Peel Hunt analyst Amy Walker, who averages the stock a purchase, said the Fresh bargain cemented her view that Oxford Bio's technology was "at the forefront of the gene & cell medication revolution".

collected by :Lucy William